ZYBT Zhengye Biotechnology Holding Ltd Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1975641
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · CNY |
|---|---|---|
| Income statement | ||
| Revenue | $16.64M | 186.36M |
| Cost of revenue | $13.23M | 95.06M |
| Gross profit | $3.41M | 91.30M |
| R&D expense | $2.58M | 12.79M |
| SG&A expense | $4.43M | 22.57M |
| Operating income | -$10.08M | 16.44M |
| Interest expense | $486,000 | 4.04M |
| Pretax income | -$10.28M | 14.39M |
| Income tax | $1.59M | 924,000 |
| Net income | -$9.98M | 11.31M |
| EBITDA | -$6.38M | 40.60M |
| EPS (basic) | — | 0.25 |
| EPS (diluted) | — | 0.25 |
| Weighted avg. shares (diluted) | 47.35M | 45.67M |
| Balance sheet | ||
| Cash & equivalents | $7.20M | 18.61M |
| Short-term investments | $223,000 | 1.43M |
| Receivables | $2.64M | 59.56M |
| Inventory | $5.60M | 58.22M |
| Current assets | $19.65M | 177.57M |
| PP&E, net | $33.86M | 255.16M |
| Intangibles | $6.73M | 14.85M |
| Total assets | $62.41M | 493.25M |
| Current liabilities | $17.23M | 135.91M |
| Short-term debt | $100,000 | 7.19M |
| Long-term debt | $1.37M | 4.80M |
| Total debt | $1.47M | 11.99M |
| Total liabilities | $18.56M | 140.71M |
| Shareholders' equity | $35.72M | 283.96M |
| Net debt | -$5.73M | -6.62M |
| Shares outstanding | — | 45.67M |
| Cash flow statement | ||
| Operating cash flow | $1.91M | 41.05M |
| Capital expenditure | $144,000 | 13.59M |
| Free cash flow | $1.77M | 27.46M |
| Investing cash flow | -$1.81M | -27.66M |
| Financing cash flow | $4.62M | -22.13M |
| Depreciation & amortization | $3.70M | 24.16M |
| Dividends paid | — | 16.02M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.